Differential effects of atypical versus typical antipsychotic medication on earnings of schizophrenia patients: Estimates from a prospective naturalistic study

PharmacoEconomics

Volumn 24, Issue 2, 2006, Pages 123-139

  Salkever, David ^a   Slade, Eric ^b   Karakus, Mustafa ^c  

^a UNIVERSITY OF MARYLAND BALTIMORE COUNTY   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; RISPERIDONE; THIORIDAZINE; TIOTIXENE; TRIFLUOPERAZINE;

ADULT; AGRANULOCYTOSIS; ARTICLE; COGNITION; DATA BASE; DRUG CHOICE; DRUG COST; ECONOMIC ASPECT; EMPLOYMENT; EMPLOYMENT STATUS; FEMALE; HUMAN; INCOME; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REGRESSION ANALYSIS; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; STATISTICAL MODEL; STATISTICAL SIGNIFICANCE;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIPSYCHOTIC AGENTS; DATABASES, FACTUAL; ECONOMICS, PHARMACEUTICAL; FEMALE; HUMANS; INCOME; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS; SCHIZOPHRENIA;

EID: 32644448821     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200624020-00003     Document Type: Article

References (51)

1. US General Accounting Office. VA health care: implementation of prescribing guideline for atypical antipsychotic drugs generally sound. GAO-02-579. Washington, DC: US Federal Government, 2002
2. Rosenheck R, Perlick D, Bingham S, et al. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. JAMA 2003; 290 (20): 2693-702
3. Bazelon center for Mental Health Law. Medicaid formulary policies: access to high-cost mental health medications. 1999 [online]. Available from URL: http://www.bazelon.org/issues/medicaid/publications/formulary.htm [Accessed 2004 Jun 8]
4. Daumit GL, Crum RM, Guallar E, et al. Outpatient prescriptions for atypical antipsychotics for African Americans, Hispanics, and Whites in the United States. Arch Gen Psychiatry 2003; 60 (2): 121-8
5. Tunis SL, Ascher-Svanum H, Stensland M, et al. Assessing the value of antipsychotics for treating schizophrenia: the importance of evaluating and interpreting the clinical significance of individual service costs. Pharmacoeconomics 2004; 22 (1): 1-8
6. Glazer WM, Johnstone BM. Pharmacoeconomic evaluation of antipsychotic therapy for schizophrenia. J Clin Psychiatry 1997; 58 Suppl. 10: 50-4
7. Hamilton SH, Revicki DA, Edgell ET, et al. Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia: results from a randomised clinical trial. Pharmacoeconomics 1999; 15 (5): 469-80
8. Percudani M, Barbui C, Tansella M. Effect of second-generation antipsychotics on employment and productivity in individuals with schizophrenia: an economic perspective. Pharmacoeconomics 2004; 22: 701-18
9. Slade E, Salkever D. Symptom effects on employment in a structural model of mental illness and treatment: analysis of patients with schizophrenia. J Ment Health Policy Econ 2001; 4: 25-34
10. Salkever DS, Slade EP. Employment retention by persons with schizophrenia employed in non-assisted jobs. J Rehabilitation 2003; 69 (4): 18-25
11. Salkever DS, Slade EP, Karakus M. Gender-specific patterns of employment and employment transitions for persons with schizophrenia: evidence from the Schizophrenia Care and Assessment Program (SCAP). In: Marcotte DE, Wilcox-Gok V, editors. Research in human capital and development: the economics of gender and mental illness. Vol. 15. Oxford (UK): Elsevier Ltd, 2004: 109-31
12. Salkever D. Tickets without takers? Potential economic barriers to the supply of rehabilitation services to beneficiaries with mental disorders. In: Rupp K, Bell SH, editors. Paying for results in vocational rehabilitation: will provider incentives work for ticket to work? Washington, DC: The Urban Institute, 2003: 327-54
13. Kapur S, Remington G. Atypical antipsychotics. BMJ 2000; 321: 1360-1
14. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 2004; 161 (3): 414-25
15. Keefe RSE, Silva SG, Perkins DO, et al. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr Bull 1999; 25: 201-22
16. Keefe RS, Seidman LJ, Christensen BK, et al. Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. Am J Psychiatry 2004; 161 (6): 985-95
17. Gold JM, Goldberg RW, McNary SW, et al. Cognitive correlates of job tenure among patients with severe mental illness. Am J Psychiatry 2002; 159: 1395-402
18. Pearlson GD, Garbacz DJ, Breakey WR, et al. Lateral ventricular enlargement associated with persistent unemployment and negative symptoms in both schizophrenia and bipolar disorder. Psychiatry Res 1984; 29 (1): 1-9
19. Mohamed S, Paulsen JS, O'Leary D, et al. Generalized cognitive deficits in schizophrenia. Arch Gen Psychiatry 1999; 56: 749-54
20. O'Leary DS, Flaum M, Kesler ML, et al. Cognitive correlates of the negative, disorganized, and psychotic symptom dimensions of schizophrenia. J Neuropsychiatry Clin Neurosci 2000; 12: 4-15
21. Addington J, Addington D, Maticka-Tyndale E. Cognitive functioning and positive and negative symptoms in schizophrenia. Schizophr Res 1991; 5: 123-34
22. Heydebrand G, Weiser M, Rabinowitz J, et al. Correlates of cognitive deficits in first episode schizophrenia. Schizophr Res 2004; 68: 1-9
23. Kirkpatrick B, Buchanan RW, Ross DE, et al. A separate disease within the syndrome of schizophrenia. Arch Gen Psychiatry 2001; 58: 165-71
24. Yen YC, Kung FW, Chong MY. Adverse effects of risperidone and haloperidol treatment in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28: 285-90
25. New Freedom Commission on Mental Health. Achieving the promise: transforming mental health care in America. Final Report. DHHS Pub. No. SMA-03-3832. Rockville (MD): US Department of Health and Human Services, Substance Abuse and Mental Health Administration, 2003
26. Crown WH, Hylan TR, Meneades L. Antidepressant selection and use and healthcare expenditures: an empirical approach. Pharmacoeconomics 1998; 4: 435-48
27. Crown WH, Obenchain RL, Englehart L, et al. The application of sample selection models to outcomes research: the case of evaluating the effects of antidepressant therapy on resource utilization. Stat Med 1998; 17: 1943-58
28. Foster EM. Is more better than less: an analysis of children. Health Serv Res 2000; 35: 1135-58
29. Hylan TR, Crown WH, Meneades L, et al. Tricyclic antidepressant and selective serotonin reuptake inhibitors antidepressant selection and health care costs in the naturalistic setting: a multivariate analysis. J Affect Disord 1998; 47: 71-9
30. Lu M. The productivity of mental health care: an instrumental variable approach. J Ment Health Policy Econ 1999; 2: 59-71
31. Mark TL, Dirani R, Slade E, et al. Access to new medications to treat schizophrenia. J Behav Health Serv Res 2002; 29: 1-15
32. Swanson JW, Swartz MS, Elbogen EB. Effectiveness of atypical antipsychotic medications in reducing violent behavior among persons with schizophrenia in community-based treatment. Schizophr Bull 2004; 30 (1): 3-20
33. US Department of Health and Human Services (USDHHS). Mental health: a report of the surgeon general. Rockville (MD): Substance Abuse and Mental Health Services Administration, Center for Mental Health Services, National Institutes of Health, National Institute of Mental Health, 1999
34. Salkever DS, Slade EP, Karakus MC. Estimation of antipsychotic effects on hospitalization risk in a naturalistic study with selection on unobservables. J Nerv Ment Dis 2004; 192 (2): 119-28
35. Maddala GS. Limited dependent and qualitative variables in econometrics. Cambridge: Cambridge University Press, 1983: 149-96
36. Averett S, Warner R, Little J, et al. Labor supply, disability benefits and mental illness. East Econ J 1999; 25 (3): 279-88
37. Wooldrige JW. Econometric analysis of cross section and panel data. Cambridge (MA): MIT Press, 2002: 521-4
38. Amemiya T. The estimation of a simultaneous equation Tobit model. Int Economic Rev 1979; 20 (1): 169-81
39. Heinrichs DW, Hanlon TE, Carpenter WT. The quality of life scale: an instrument for rating the schizophrenia deficit syndrome. Schizophr Bull 1984; 10: 388-99
40. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261-76
41. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382-9
42. Lehman AF. The well-being of chronic mental patients: assessing their quality of life. Arch Gen Psychiatry 1983; 40: 369-73
43. Domino ME, Frank RG, Rosenheck R. The diffusion of new antipsychotic medications and formulary policy. Schizophr Bull 2003; 29: 95-104
44. Sargan JD. The estimation of economic relationships using instrumental variables. Econometrica 1958; 26: 393-415
45. Lichtenberg FR, Philipson TJ. The dual effects of intellectual property regulations: within- and between-patent competition in the US pharmaceutical industry. National Bureau of Economic Research Working Paper 9303. 2002 Oct [online]. Available from URL: http://www.nber.org [Accessed 2004 Jun 8]
46. Frank RG, Berndt ER, Busch AB, et al. Quality-constant "prices" for the ongoing treatment of schizophrenia: an exploratory study. Quart Rev of Economics and Finance 2004; 44 (3): 390-409
47. Social Security Administration (2002). Ticket to work and work incentives advisory panel. Advice Report to the Commissioner of Social Security: statutory requirements and design issues related to SSDI $1 for $2 Benefit Offset Research, 2002 [online]. Available from URL: http://www.ssa.gov/work/ panel/panel_documents/1for2advicereport.html [Accessed 2004 Jun 8]
48. Center for Medicare and Medicaid Services. Current enrollments in the Medicaid buy-in as of March 31, 2003 [online]. Available from URL: http://www.cms.hhs.gov/twwiia/enrollmentperstate.pdf [Accessed 2004 Jul 17]
49. Rosenheck R, Cramer J, Xu WE, et al. A comparison of clozapine and haoloperidol in hospitalized patients with refractory schizophrenia. N Engl J Med 1997; 337: 809-15
50. Hamilton SH, Edgell ET, Revicki DA, et al. Functional outcomes in schizophrenia: a comparison of olanzapine and haloperidol in a European sample. Int Clin Psychopharmacol 2000; 15: 2245-55
51. Meyer PS, Bond GR, Tunis SL, et al. Comparison between effects of atypical and traditional antipsychotics on work status for clients in a psychiatric rehabilitation program. J Clin Psychiatry 2002; 63: 108-16